Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2014

01.09.2014 | Clinical trial

Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients

verfasst von: Isabel T. Rubio, Martin Espinosa-Bravo, Maxi Rodrigo, Maria Amparo Viguri Diaz, David Hardisson, Amaia Sagasta, Basilio Dueñas, Vicente Peg

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Several models have been developed to predict non-sentinel nodes (NSLN) metastasis in patients with a positive sentinel node (SLN) that incorporates a standard pathology examination of the SLN. It has been reported that total tumoral load (TTL) in the SLNs assessed by one-step nucleic acid amplification (OSNA) is a predictive factor for additional NSLN metastasis in the axillary lymph node dissection (ALND). The objective was to develop a nomogram that predicts patient´s risk of additional NSLN metastasis incorporating TTL in the SLNs assessed by OSNA. Six hundred and ninety-seven consecutive patients with positive SLN evaluation by OSNA and a completion ALND were recruited. Pathologic features of the primary tumor and SLN metastases, including TTL were collected. Multivariate logistic regression identified factors predictive of non-SLN metastasis. A nomogram was developed with these variables and validated in an external cohort. On multivariate logistic regression analysis, tumor size, number of affected SLN, Her2 overexpression, lymphovascular invasion, and TTL were each associated with the likelihood of additional NSLN metastasis (p < 0.05). The overall predictive accuracy of the nomogram, as measured by the AUC was 0.7552 (95 %CI 0.7159–0.7945). When applied to the external cohort the nomogram was accurate with an AUC = 0.678 (95 %CI 0.621–0.736). This novel nomogram that incorporates TTL assessed by OSNA performs well and may help clinicians to make decisions about ALND for individual patients. Moreover, the standardization of pathologic assessment by OSNA may help to achieve interinstitutional reproducibility among nomograms.
Literatur
1.
Zurück zum Zitat Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Constantino JP et al (2010) Sentinel lymph node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927–933PubMedCentralPubMedCrossRef Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Constantino JP et al (2010) Sentinel lymph node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927–933PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V et al (2006) Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 7(12):983–990PubMedCrossRef Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V et al (2006) Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 7(12):983–990PubMedCrossRef
3.
Zurück zum Zitat Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 98:599–600PubMedCrossRef Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 98:599–600PubMedCrossRef
4.
Zurück zum Zitat Abdessalam SF, Zervos EE, Prasad M, Farrar WB, Yee LD, Walker MJ et al (2001) Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg 182:316–320PubMedCrossRef Abdessalam SF, Zervos EE, Prasad M, Farrar WB, Yee LD, Walker MJ et al (2001) Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg 182:316–320PubMedCrossRef
5.
Zurück zum Zitat Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Berstein F, Kuerer HM et al (2007) Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 110(4):723–730PubMedCrossRef Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Berstein F, Kuerer HM et al (2007) Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 110(4):723–730PubMedCrossRef
6.
Zurück zum Zitat Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM et al (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastasis: the American College of Surgeons Oncology group z0011 randomized trial. Ann Surg 252:426–432PubMed Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM et al (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastasis: the American College of Surgeons Oncology group z0011 randomized trial. Ann Surg 252:426–432PubMed
7.
Zurück zum Zitat Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK et al (2003) A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10:1140–1151PubMedCrossRef Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK et al (2003) A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10:1140–1151PubMedCrossRef
8.
Zurück zum Zitat Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S (2005) An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat 91:113–119PubMedCrossRef Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S (2005) An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat 91:113–119PubMedCrossRef
9.
Zurück zum Zitat Saidi RF, Dudrick PS, Remine SG, Mittal VK (2004) Nonsentinel lymph node status after positive sentinel lymph node biopsy in early breast cancer. Am Surg 70:101–105PubMed Saidi RF, Dudrick PS, Remine SG, Mittal VK (2004) Nonsentinel lymph node status after positive sentinel lymph node biopsy in early breast cancer. Am Surg 70:101–105PubMed
10.
Zurück zum Zitat Degnim AC, Reynolds C, Pantvaidya G, Zakaria S, Hoskin T, Barnes S et al (2005) Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg 190:543–550PubMedCrossRef Degnim AC, Reynolds C, Pantvaidya G, Zakaria S, Hoskin T, Barnes S et al (2005) Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg 190:543–550PubMedCrossRef
11.
Zurück zum Zitat Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S et al (2008) New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 8:66PubMedCentralPubMedCrossRef Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S et al (2008) New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 8:66PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD (2008) A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 95:302–309PubMedCrossRef Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD (2008) A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 95:302–309PubMedCrossRef
13.
Zurück zum Zitat Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R et al (2012) Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 255:109–115PubMedCrossRef Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R et al (2012) Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 255:109–115PubMedCrossRef
14.
Zurück zum Zitat Bolster MJ, Peer PG, Bult P, Thunnissen FB, Schapers RF, Meijer JW et al (2007) Risk factors for non sentinel lymph node metastases in patients with breast cancer. The outcome of a multi-institutional study. Ann Surg Oncol 14:181–189PubMedCrossRef Bolster MJ, Peer PG, Bult P, Thunnissen FB, Schapers RF, Meijer JW et al (2007) Risk factors for non sentinel lymph node metastases in patients with breast cancer. The outcome of a multi-institutional study. Ann Surg Oncol 14:181–189PubMedCrossRef
15.
Zurück zum Zitat Ozmen V, Karanlik H, Cabioglu N, Igci A, Kecer M, Asoglu O et al (2006) Factors predicting the sentinel and non sentinel lymph node metastases in breast cancer. Breast Cancer Res Treat 95:1–6PubMedCrossRef Ozmen V, Karanlik H, Cabioglu N, Igci A, Kecer M, Asoglu O et al (2006) Factors predicting the sentinel and non sentinel lymph node metastases in breast cancer. Breast Cancer Res Treat 95:1–6PubMedCrossRef
16.
Zurück zum Zitat Patani N, Mokbel K (2009) The clinical significance of sentinel lymph node micrometastasis in breast cancer. Breast Cancer Res Treat 114:393–402PubMedCrossRef Patani N, Mokbel K (2009) The clinical significance of sentinel lymph node micrometastasis in breast cancer. Breast Cancer Res Treat 114:393–402PubMedCrossRef
17.
Zurück zum Zitat Castellano I, Macri L, Deambrogio C, Balmativola D, Bussone R, Ala A et al (2011) Reliability of whole sentinel lymph node analysis by one-step nucleic acid amplification for intraoperative diagnosis of breast cancer metastases. Ann Surg 00:1–9 Castellano I, Macri L, Deambrogio C, Balmativola D, Bussone R, Ala A et al (2011) Reliability of whole sentinel lymph node analysis by one-step nucleic acid amplification for intraoperative diagnosis of breast cancer metastases. Ann Surg 00:1–9
18.
Zurück zum Zitat Cserni G (2012) Intraoperative analysis of sentinel lymph nodes in breast cancer by one-step nucleic acid amplification. J Clin Pathol 65(3):193–199PubMedCrossRef Cserni G (2012) Intraoperative analysis of sentinel lymph nodes in breast cancer by one-step nucleic acid amplification. J Clin Pathol 65(3):193–199PubMedCrossRef
19.
Zurück zum Zitat Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F et al (2007) One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 13:4807–4816PubMedCrossRef Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F et al (2007) One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 13:4807–4816PubMedCrossRef
20.
Zurück zum Zitat Visser M, Jiwa M, Horstman A, Brink AA, Pol RP, van Diest P et al (2008) Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. Int J Cancer 122:2562–2567PubMedCentralPubMedCrossRef Visser M, Jiwa M, Horstman A, Brink AA, Pol RP, van Diest P et al (2008) Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. Int J Cancer 122:2562–2567PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Tamaki Y, Akiyama F, Iwase T, Kaneko T, Tsuda H, Sato K, Ueda S et al (2009) Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res 15:2879–2884PubMedCrossRef Tamaki Y, Akiyama F, Iwase T, Kaneko T, Tsuda H, Sato K, Ueda S et al (2009) Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res 15:2879–2884PubMedCrossRef
22.
Zurück zum Zitat Espinosa-Bravo M, Sansano I, Pérez-Hoyos S, Ramos M, Sancho M, Xercavins J et al (2013) Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay. Eur J Surg Oncol 39(7):766–773PubMedCrossRef Espinosa-Bravo M, Sansano I, Pérez-Hoyos S, Ramos M, Sancho M, Xercavins J et al (2013) Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay. Eur J Surg Oncol 39(7):766–773PubMedCrossRef
23.
Zurück zum Zitat Peg V, Espinosa-Bravo M, Vieites B, Vilardell F, Antúnez JR, de Salas MS et al (2013) Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients. Breast Cancer Res Treat 139(1):87–93PubMedCrossRef Peg V, Espinosa-Bravo M, Vieites B, Vilardell F, Antúnez JR, de Salas MS et al (2013) Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients. Breast Cancer Res Treat 139(1):87–93PubMedCrossRef
24.
Zurück zum Zitat Rubio IT, Aznar F, Lirola J, Peg V, Xervacins J et al (2010) Intraoperative assessment of sentinel lymph nodes after neoadjuvant chemotherapy in patients with breast cancer. Ann Surg Oncol 17(1):235–239PubMedCrossRef Rubio IT, Aznar F, Lirola J, Peg V, Xervacins J et al (2010) Intraoperative assessment of sentinel lymph nodes after neoadjuvant chemotherapy in patients with breast cancer. Ann Surg Oncol 17(1):235–239PubMedCrossRef
25.
Zurück zum Zitat Edge SBBD, Compton CC, Fritz AG et al (2010) AJCC cancer staging manual, 7th edn. Springer, New York Edge SBBD, Compton CC, Fritz AG et al (2010) AJCC cancer staging manual, 7th edn. Springer, New York
26.
Zurück zum Zitat Steyerberg EW, Borsboom GJ, van Houwelingen HC, Eijkemans MJ, Habbema JD (2004) Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med 23:2567–2586PubMedCrossRef Steyerberg EW, Borsboom GJ, van Houwelingen HC, Eijkemans MJ, Habbema JD (2004) Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med 23:2567–2586PubMedCrossRef
27.
Zurück zum Zitat Feldman S, Krishnamurthy S, Gillanders W, Gittleman M, Beitsch PD, Young PR et al (2011) A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer 117(12):2599–2607PubMedCrossRef Feldman S, Krishnamurthy S, Gillanders W, Gittleman M, Beitsch PD, Young PR et al (2011) A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer 117(12):2599–2607PubMedCrossRef
28.
Zurück zum Zitat Osako T, Iwase T, Kimura K, Horii R, Akiyama F (2013) Sentinel tumor burden quantified based on cytokeratin 19 mRNA copy number predicts non sentinel node metastases in breast cáncer: molecular whole-node analysis of all removed nodes. Eur J Cancer 49(6):1187–1196PubMedCrossRef Osako T, Iwase T, Kimura K, Horii R, Akiyama F (2013) Sentinel tumor burden quantified based on cytokeratin 19 mRNA copy number predicts non sentinel node metastases in breast cáncer: molecular whole-node analysis of all removed nodes. Eur J Cancer 49(6):1187–1196PubMedCrossRef
29.
Zurück zum Zitat Meretoja TJ, Leidenius MH, Heikkila PS, Boross G, Sejben I, Regitnig P et al (2012) International multicenter tool to predict the risk of nonsentinel node metastasis in breast cancer. J Natl Cancer Inst 104(24):1888–1896PubMedCrossRef Meretoja TJ, Leidenius MH, Heikkila PS, Boross G, Sejben I, Regitnig P et al (2012) International multicenter tool to predict the risk of nonsentinel node metastasis in breast cancer. J Natl Cancer Inst 104(24):1888–1896PubMedCrossRef
30.
Zurück zum Zitat Crabb SJ, Cheand MC, Leung S, Immonen T, Nielsen TO, Huntsman DD et al (2008) Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metàstasis in primary breast cancer. Clin Breast Cancer 8:249–256PubMedCrossRef Crabb SJ, Cheand MC, Leung S, Immonen T, Nielsen TO, Huntsman DD et al (2008) Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metàstasis in primary breast cancer. Clin Breast Cancer 8:249–256PubMedCrossRef
31.
Zurück zum Zitat Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S et al (2009) Axillary lymph node status of operable breast càncers by combined steroid receptor and Her2 status: triple positive tumors are more likely lymph node positive. Breast Cancer Res Treat 113:181–187PubMedCrossRef Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S et al (2009) Axillary lymph node status of operable breast càncers by combined steroid receptor and Her2 status: triple positive tumors are more likely lymph node positive. Breast Cancer Res Treat 113:181–187PubMedCrossRef
32.
Zurück zum Zitat Jones T, Neboori H, Wu H, Yang Q, Haffty BG, Evans S et al (2013) Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early stage breast càncer? Ann Surg Oncol 20(9):2866–2872PubMedCrossRef Jones T, Neboori H, Wu H, Yang Q, Haffty BG, Evans S et al (2013) Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early stage breast càncer? Ann Surg Oncol 20(9):2866–2872PubMedCrossRef
33.
Zurück zum Zitat Coutant C, Olivier C, Lambaudie E, Fondrinier E, Marchai F, Guillemin F et al (2009) Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. JCO 27:2800–2808CrossRef Coutant C, Olivier C, Lambaudie E, Fondrinier E, Marchai F, Guillemin F et al (2009) Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. JCO 27:2800–2808CrossRef
34.
Zurück zum Zitat Klar M, Jochmann A, Foeldi M, Stumpf M, Gitsch G, Stickeler E, Watermann D (2008) The MSKCC nomogram for prediction the likelihood of non sentinel node involvement in a German breast cancer population. Breast Cancer Res Treat 112:523–531PubMedCrossRef Klar M, Jochmann A, Foeldi M, Stumpf M, Gitsch G, Stickeler E, Watermann D (2008) The MSKCC nomogram for prediction the likelihood of non sentinel node involvement in a German breast cancer population. Breast Cancer Res Treat 112:523–531PubMedCrossRef
35.
Zurück zum Zitat Andersson Y, Frisell J, de Boniface J, Bergkvist L (2012) Prediction of non sentinel node status in breast cancer patients with sentinel lymph node metastases: evaluation of the Tenon Score. Breast Cancer Clin Res 6:31–38CrossRef Andersson Y, Frisell J, de Boniface J, Bergkvist L (2012) Prediction of non sentinel node status in breast cancer patients with sentinel lymph node metastases: evaluation of the Tenon Score. Breast Cancer Clin Res 6:31–38CrossRef
36.
Zurück zum Zitat Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ (2005) Predicting nonsentinel node status after positive lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 12(8):654–658PubMedCrossRef Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ (2005) Predicting nonsentinel node status after positive lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 12(8):654–658PubMedCrossRef
37.
Zurück zum Zitat Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A et al (2012) American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol 19(10):3144–3151PubMedCrossRef Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A et al (2012) American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol 19(10):3144–3151PubMedCrossRef
38.
Zurück zum Zitat Latosinsky S, Berrang TS, Cutter CS, George R, Olivotto I, Julian TB (2012) Axillary dissection versus non axillary dissection in women with invasive breast cancer and sentinel node metástasis. Can J Surg 55:66–69PubMedCentralPubMedCrossRef Latosinsky S, Berrang TS, Cutter CS, George R, Olivotto I, Julian TB (2012) Axillary dissection versus non axillary dissection in women with invasive breast cancer and sentinel node metástasis. Can J Surg 55:66–69PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Massimino KP, Hessman CJ, Ellis MC, Naik AM, Vetto JT (2012) Impact of American College of Surgeons Oncology Group Z0011 and National Surgical Adjuvant Breast and Bowel Project B-32 trial results on surgeon practice in the Pacific Northwest. Am J Surg 203(5):618–622PubMedCrossRef Massimino KP, Hessman CJ, Ellis MC, Naik AM, Vetto JT (2012) Impact of American College of Surgeons Oncology Group Z0011 and National Surgical Adjuvant Breast and Bowel Project B-32 trial results on surgeon practice in the Pacific Northwest. Am J Surg 203(5):618–622PubMedCrossRef
40.
Zurück zum Zitat Loveland-Jones CE, Ruth K, Sigurdson ER, Egleston BL, Boraas M, Bleicher RJ (2014) Patterns of nodal staging during breast conservation surgery in the medicare patient: will the ACOSOG Z0011 trial change the pattern of care? Breast Cancer Res Treat 143(3):571–577PubMedCrossRef Loveland-Jones CE, Ruth K, Sigurdson ER, Egleston BL, Boraas M, Bleicher RJ (2014) Patterns of nodal staging during breast conservation surgery in the medicare patient: will the ACOSOG Z0011 trial change the pattern of care? Breast Cancer Res Treat 143(3):571–577PubMedCrossRef
41.
Zurück zum Zitat Caudle A, Hunt KK, Kuerer HM, Meric-Berstein F, Lucci A, Bedrosian I, Babiera GV et al (2011) Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol 18(9):2407–2412PubMedCrossRef Caudle A, Hunt KK, Kuerer HM, Meric-Berstein F, Lucci A, Bedrosian I, Babiera GV et al (2011) Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol 18(9):2407–2412PubMedCrossRef
Metadaten
Titel
Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients
verfasst von
Isabel T. Rubio
Martin Espinosa-Bravo
Maxi Rodrigo
Maria Amparo Viguri Diaz
David Hardisson
Amaia Sagasta
Basilio Dueñas
Vicente Peg
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3108-2

Weitere Artikel der Ausgabe 2/2014

Breast Cancer Research and Treatment 2/2014 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.